The Experts below are selected from a list of 1398 Experts worldwide ranked by ideXlab platform

René Prêtre - One of the best experts on this subject based on the ideXlab platform.

  • Survival After Surgical Drainage of Malignant Pericardial Effusion
    World Journal of Surgery, 2015
    Co-Authors: Lars Niclauss, Michael Montemurro, René Prêtre
    Abstract:

    Objectives Management of malignant Pericardial effusion (PE) is complex. Cardiac surgeons are not necessarily familiar with or are challenged by the many underlying etiologies. Analyzing risk factors for mortality may help to estimate the benefit of surgery in high-risk patients. Methods Patients undergoing a surgical pericardiotomy for malignant PE, between 2001 and 2011, were included. The influence of Tumor type, disease extension, intra-Pericardial Tumor infiltration on early mortality and long-term survival as well as freedom from symptoms after drainage, and the use of sclerosing agents on PE recurrence rates was analyzed. Results PE drainage was performed on 46 patients 12 ± 30 months after Tumor diagnosis. Malignant diseases were lung cancers (50 %), breast cancers (15 %), lymphoma and leukemia (13 %), cancers of the digestive tract (13 %), and others (9 %). 80 % of patients were symptomatic and symptom relief was achieved in 65 %. Nobody died during surgery. Recurrence rate was 4 %. Early in-hospital mortality was 22 %. After 1 year, 29 % of patients were alive. Eleven patients (24 %) had a complete Tumor regression. Metastatic spread ( p  

Lars Niclauss - One of the best experts on this subject based on the ideXlab platform.

  • Survival After Surgical Drainage of Malignant Pericardial Effusion
    World Journal of Surgery, 2015
    Co-Authors: Lars Niclauss, Michael Montemurro, René Prêtre
    Abstract:

    Objectives Management of malignant Pericardial effusion (PE) is complex. Cardiac surgeons are not necessarily familiar with or are challenged by the many underlying etiologies. Analyzing risk factors for mortality may help to estimate the benefit of surgery in high-risk patients. Methods Patients undergoing a surgical pericardiotomy for malignant PE, between 2001 and 2011, were included. The influence of Tumor type, disease extension, intra-Pericardial Tumor infiltration on early mortality and long-term survival as well as freedom from symptoms after drainage, and the use of sclerosing agents on PE recurrence rates was analyzed. Results PE drainage was performed on 46 patients 12 ± 30 months after Tumor diagnosis. Malignant diseases were lung cancers (50 %), breast cancers (15 %), lymphoma and leukemia (13 %), cancers of the digestive tract (13 %), and others (9 %). 80 % of patients were symptomatic and symptom relief was achieved in 65 %. Nobody died during surgery. Recurrence rate was 4 %. Early in-hospital mortality was 22 %. After 1 year, 29 % of patients were alive. Eleven patients (24 %) had a complete Tumor regression. Metastatic spread ( p  

Michael Montemurro - One of the best experts on this subject based on the ideXlab platform.

  • Survival After Surgical Drainage of Malignant Pericardial Effusion
    World Journal of Surgery, 2015
    Co-Authors: Lars Niclauss, Michael Montemurro, René Prêtre
    Abstract:

    Objectives Management of malignant Pericardial effusion (PE) is complex. Cardiac surgeons are not necessarily familiar with or are challenged by the many underlying etiologies. Analyzing risk factors for mortality may help to estimate the benefit of surgery in high-risk patients. Methods Patients undergoing a surgical pericardiotomy for malignant PE, between 2001 and 2011, were included. The influence of Tumor type, disease extension, intra-Pericardial Tumor infiltration on early mortality and long-term survival as well as freedom from symptoms after drainage, and the use of sclerosing agents on PE recurrence rates was analyzed. Results PE drainage was performed on 46 patients 12 ± 30 months after Tumor diagnosis. Malignant diseases were lung cancers (50 %), breast cancers (15 %), lymphoma and leukemia (13 %), cancers of the digestive tract (13 %), and others (9 %). 80 % of patients were symptomatic and symptom relief was achieved in 65 %. Nobody died during surgery. Recurrence rate was 4 %. Early in-hospital mortality was 22 %. After 1 year, 29 % of patients were alive. Eleven patients (24 %) had a complete Tumor regression. Metastatic spread ( p  

Seiichi Tamaj - One of the best experts on this subject based on the ideXlab platform.

  • vacuolated cell mesothelioma of the pericardium resembling liposarcoma a case report
    Human Pathology, 2000
    Co-Authors: Hideyuki Shimazaki, Shinsuke Aida, Yasuhiro Iizuka, Hiroshi Yoshizu, Seiichi Tamaj
    Abstract:

    Abstract We report a case of localized Pericardial mesothelioma with unusual histological features in a 44-year-old woman. Her radiological imagings showed an 11-cm Pericardial Tumor, between the heart and aortic arch. Microscopically, the Tumor was predominantly composed of vacuolated cells and vaguely reminiscent of well differentiated “lipoma-like” liposarcoma, but only small foci of the Tumor showed the papillotubular configuration. Histochemically, the Tumor cells contained hyaluronic acid in the vacuoles but no lipids. Immunohistochemically, they showed immunoreactivity for cytokeratin, calretinin, vimentin, and epithelial membrane antigen. Ultrastructural study showed that the vacuoles of the Tumor cells were intracytoplasmic lumina. The intracytoplasmic lamina and the surface membranes of the Tumor cells had many long and slender microvilli with focal bush-like appearance. Desmosomes between adjacent cells were occasionally observed. To our knowledge, this is the first case report of epithelial type mesothelioma predominantly composed of vacuolated Tumor cells, microscopically mimicking liposarcoma.

Prêtre R. - One of the best experts on this subject based on the ideXlab platform.

  • Survival after surgical drainage of malignant Pericardial effusion.
    'Springer Science and Business Media LLC', 2015
    Co-Authors: Niclauss L., Montemurro M., Prêtre R.
    Abstract:

    OBJECTIVES: Management of malignant Pericardial effusion (PE) is complex. Cardiac surgeons are not necessarily familiar with or are challenged by the many underlying etiologies. Analyzing risk factors for mortality may help to estimate the benefit of surgery in high-risk patients. METHODS: Patients undergoing a surgical pericardiotomy for malignant PE, between 2001 and 2011, were included. The influence of Tumor type, disease extension, intra-Pericardial Tumor infiltration on early mortality and long-term survival as well as freedom from symptoms after drainage, and the use of sclerosing agents on PE recurrence rates was analyzed. RESULTS: PE drainage was performed on 46 patients 12 ± 30 months after Tumor diagnosis. Malignant diseases were lung cancers (50 %), breast cancers (15 %), lymphoma and leukemia (13 %), cancers of the digestive tract (13 %), and others (9 %). 80 % of patients were symptomatic and symptom relief was achieved in 65 %. Nobody died during surgery. Recurrence rate was 4 %. Early in-hospital mortality was 22 %. After 1 year, 29 % of patients were alive. Eleven patients (24 %) had a complete Tumor regression. Metastatic spread (p < 0.001), Pericardial infiltration (p = 0.02), and intra-Pericardial Bleomycin (p = 0.01) injection were associated with increased mortality. Hematological malignancies had a better prognosis for survival. CONCLUSION: Surgical pericardiotomy is safe, associated with a low recurrence rate and symptom relief in the majority of dyspneic patients. Intra-Pericardial Bleomycin may reduce recurrent effusion but does not ameliorate survival. Long-term survival rate was low with an increased mortality in cases of metastatic spreading, Pericardial infiltration, and as the Tumor of origin: breast cancers. Leukemic and lymphatic Tumors have better prognosis